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directly targets the oncogene DDHD2 by
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Background: The pathways regulating the transition of mammalian cells from quiescence to proliferation are
mediated by multiple miRNAs. Despite significant improvements in our understanding of miRNA targeting, the
majority of miRNA regulatory networks are still largely unknown and require experimental validation.
Results: Here we identified miR-503, miR-103, and miR-494 as negative regulators of proliferation in primary human
cells. We experimentally determined their genome wide target profiles using RNA-induced silencing complex (RISC)
immunoprecipitations and gene expression profiling. Analysis of the genome wide target profiles revealed evidence
of extensive regulation of gene expression through non-canonical target pairing by miR-503. We identified the
proto-oncogene DDHD2 as a target of miR-503 that requires pairing outside of the canonical 5′ seed region of
miR-503, representing a novel mode of miRNA-target pairing. Further bioinformatics analysis implicated miR-503
and DDHD2 in breast cancer tumorigenesis.
Conclusions: Our results provide an extensive genome wide set of targets for miR-503, miR-103, and miR-494,
and suggest that miR-503 may act as a tumor suppressor in breast cancer by its direct non-canonical targeting
of DDHD2.
Keywords: miRNA, miRNA targeting, Proliferation, Ago2 immunoprecipitation, RIP-seq, miRNA targets, miRNA target
pairing, miR-503, miRNA non-canonical pairingIntroduction
The ability of human cells to transition from a quiescent
to proliferative state is essential for tissue homeostasis.
The majority of cells in an adult organism primarily exist
in a quiescent state that is actively maintained by mul-
tiple genetic programs [1-3]. Maintenance of prolifera-
tive potential and the ability of cells to re-enter the cell
cycle upon appropriate stimuli are vital for numerous
physiological processes, including lymphocyte activation,
hepatocyte regeneration, and wound healing [4-7]. The
transition from quiescence to proliferation is exquisitely
controlled by multiple check-points and fail-safe me-
chanisms, but is still susceptible to deregulation if the
signaling pathways involved are sufficiently perturbed.
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unless otherwise stated.and sustained proliferative signaling are two of the basic
requirements for tumorigenesis [8].
One of the main classes of regulators mediating cell pro-
liferation and tumorigenesis are miRNAs [5,9]. miRNAs
are short noncoding RNAs that post-transcriptionally
regulate gene expression. They are ubiquitous regulators
of multiple cellular pathways and biological processes
such as metabolism, immune defense, development, dif-
ferentiation, proliferation, and apoptosis [10,11]. miRNAs
are predicted to regulate ~50% of all human protein cod-
ing genes [11], and have been shown to be involved in
numerous pathologies, such as cardiovascular disease,
viral diseases, and cancer development [12-14]. Mul-
tiple miRNAs are known to act as either tumor sup-
pressors or oncogenes, and miRNAs are located in ~50%
of all fragile regions in the genome or regions that are
commonly amplified or deleted in cancers [15].
Genome wide gene expression profiling after miRNA
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pairing is mediated through perfect pairing of the seed
region [12,16,17]. More recently, methodologies used
to profile genome wide RISC occupancy have revealed
extensive RISC binding to transcripts with imperfect or
nonexistent seed matches [18-21]. This non-canonical
miRNA-target pairing has been observed to occur in
up to 60% of miRNA-target pairs [5,9,18]. However,
regulation of gene expression by non-canonical target
pairing was shown to be modest at best, and observed
to have no significant effect on gene expression in
multiple studies [12,16,17,20,21].
miR-503, miR-103, and miR-494 have previously been
shown to act as either oncogenes or tumor suppressors
in different cellular contexts [22-29]. miR-103 has been
described to function as an oncomiR in colorectal cancer
and breast cancer [22,27]. miR-494 has been reported to
function as an oncomiR in colorectal cancer and non-
small cell lung cancer [23,24], and as a tumor suppressor
in cholangiocarcinoma and gastrointestinal stromal tu-
mors [25,28]. miR-503 acts as a tumor suppressor in
non-small cell lung cancer, glioblastoma, and hepatocel-
lular carcinoma [26,30-33], and as an oncomiR in colon
cancer [29]. Despite the broad involvement of miR-503
in repressing tumorigenesis in various cancers, its activity
has not been explored in either primary cells or breast
cancer.
In this study, we investigated the regulation of cell
proliferation in primary human cells by miR-503, miR-
103, and miR-494. We identified a genome wide set of
the targets of miR-503, −103, and −494 by conducting
extensive profiling of RISC associated transcripts and
gene expression profiling. Analysis of the experimentally
determined miRNA targetomes indicated utilization of
non-canonical target pairing. We further explored the tar-
geting mechanisms of miR-503 experimentally, and con-
firmed that miR-503 targets the proto-oncogene DDHD2
through a novel form of non-canonical target pairing.
Additional bioinformatic analysis revealed a link between
miR-503, DDHD2, and breast cancer.
Results
miR-503, miR-103, and miR-494 repress proliferation
miRNAs that regulate proliferation are differentially
expressed in quiescent and proliferating primary human
fibroblasts [34]. Using previously published data we identi-
fied numerous miRNAs induced in fibroblasts transition-
ing from quiescence to proliferation, and selected three,
miR-503, miR-103, and miR-494, for further study that
were consistently induced by serum stimulation and
predicted to target proliferation and or cell cycle related
genes [34].
To investigate the effect of miR-503, miR-103, and
miR-494 on cell proliferation, we transiently overexpressedeach of these miRNAs in proliferating fibroblasts and
assayed the rate of cell growth. Surprisingly, cells with
transiently overexpressed miR-503, −103, or −494 showed
significant reductions in the rate of cell growth (Figure 1A).
miRNAs induced by serum stimulation were expected to
increase proliferation, but there are numerous examples
of miRNAs that participate in negative feedback loops
[34-36]. To confirm their effect on cell growth, we overex-
pressed miR-503, −103, −494, and miR-34a, a well known
tumor suppressor [37], in proliferating fibroblasts and
counted cells expressing Ki67 protein using flow cytome-
try. miR-503 and −494 transient overexpression signifi-
cantly decreased the percentage of Ki67 positive cells
compared to multiple controls, indicating that these miR-
NAs repress proliferation, although not to the extent of
miR-34a (Figure 1B) [37]. In addition, transient overex-
pression of miR-503 and −103 in proliferating fibroblasts
significantly decreased the rate of progression through the
cell cycle (Figure 1C). To rule out indirect effects from
flooding the cells and the RNA silencing machinery with
large quantities of the mature miRNA duplexes, we transi-
ently inhibited miR-503, −103, and −494 in fibroblasts
induced into quiescence by serum removal. Inhibition of
miR-503, −103, and −494 in quiescent fibroblasts signifi-
cantly increased the rate of cell growth (Figure 1D). Taken
together, these data indicated that all 3 of these miRNAs
inhibit cell growth, with miR-503 most clearly regulating
proliferation and cell cycle progression.
Genome wide profiling of miR-503, −103, and −494
targets
To experimentally identify the targets of miR-503, −103,
and −494 we used two approaches. First, we identified
transcripts isolated from RISC immunoprecipitations
(RIPs) following transient overexpression of each of the
three miRNAs, using microarrays (RIP-chip) or deep se-
quencing (RIP-seq) (Figure 2). To immunoprecipitate
RISC, we used a monoclonal antibody directed against
Argonaute-2, an essential component of RISC [16]. RISC
is directed to target mRNAs by the mature miRNA guide
strand [16]. Increases in RISC association with a given
transcript following miRNA overexpression indicate direct
targets of the overexpressed miRNA. Second, we carried
out gene expression profiling after transient overexpres-
sion of the miRNAs (Figure 2). RNA-Seq and microarray
experiments were well correlated for both RIP and gene
expression (Additional file 1). RIP enrichment was defined
as an increase in RISC association with a given transcript
following miRNA transfection compared to the control
transfection. Enrichment indicates mRNAs associated
with RISC in an miRNA dependent manner. To obtain
enough RNA for successful genome wide profiling, all
RIPs and gene expression experiments were conduc-
ted in HeLa cells, due to HeLa cells having a greater
Figure 1 miR-503, −103, and −494 inhibit proliferation. (A) miR-503, −103, and −494 transfection significantly reduces primary human
fibroblast cell growth. Average cell number relative to 0 hr following miRNA or Control siRNA transfection is shown for each time point indicated.
Error bars denote ± SD, n = 6. P-values were calculated by Student’s t-test comparing cell numbers following miRNA transfection to cell numbers
following Control siRNA transfection at each time point. (B) miR-503 and −494 transfection significantly represses proliferation. The Y-axis indicates
the relative percentage of primary human fibroblast cells expressing Ki67, measured by flow cytometry. Bars are the mean percentage of cells
expressing Ki67 relative to Control RNA 2, and error bars denote ± SD, n = 3. (C) miR-503 and −103 transfection significantly inhibits progression
through the cell cycle. The Y-axis indicates the percentage of primary human fibroblast cells found in each stage of the cell cycle measured using
propidium iodide staining, and bars are the mean percentage the cell population found in each stage. Error bars denote ± SD, n = 3. (D) Inhibition
of miR-503, −103, and −494 increases cell growth in quiescent fibroblasts. Average cell number relative to 0 hr following transfection of an LNA
targeting miR-503, −103, or −494 or a LNA negative control is shown for each time point indicated. Error bars denote ± SD, n = 6. P-values were
calculated by Student’s one tailed t-test comparing cell numbers following miRNA inhibitor transfection to cell numbers following Control
inhibitor transfection at each time point. For B, P-values were estimated by Student’s t-test, and for C, P-values were estimated by Student’s paired
t-test. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.
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fibroblasts.
To determine if the RIPs effectively identified miRNA
targets, we first examined whether miRNA dependent
mRNA association with RISC was accompanied by cor-
responding decreases in transcript levels. For all mRNAs
profiled, the level of RISC association correlated well
with repression of gene expression (Pearson correlation
between RIP-seq enrichment and RNA-seq gene expres-
sion repression was 0.65, 0.63, and 0.58 for miR-503,−103, and −494 respectively). In addition, mRNAs that
displayed miRNA dependent RISC association were
significantly more repressed than all mRNAs profiled
(Figure 3A). mRNAs that associated with RISC in a
miRNA dependent manner were also significantly more
repressed than all mRNAs containing the respective 7-
mer miRNA seed match in their 3′UTR, indicating the
RIPs more successfully identified mRNA targets than
using presence of the seed match as the only criteria
(Figure 3A).
Figure 2 Strategy for genome-wide target identification of miRNAs using RIP and gene expression profiling. HeLa cells are transfected
either with miRNAs or control duplexes. From each transfection, total RNA as well as RISC-associated RNAs are isolated by Ago2 immunoprecipitation.
All populations of RNAs are profiled by deep sequencing or in come cases, by microarray hybridization (see text). RNAs showing RISC-association in a
miRNA dependent manner are identified by comparing the immunoprecipitated RNAs between the miRNA and control RNA transfection. mRNAs
showing repression by the miRNAs are identified by comparing the total RNAs between the miRNA and control RNA transfection.
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miRNA target identification, we examined miRNA seed
match frequency in mRNAs associated with RISC in a
miRNA dependent manner. Following transient miR-
503, −103, and −494 overexpression, mRNAs with the
greatest RISC association had a high frequency of the
corresponding miRNA seed matches (Figure 3B). In ad-
dition, mRNAs that were most repressed following miRNA
transient overexpression showed the greatest enrichment
for miR-103, and −494 seed matches, although not for
miR-503 (Figure 3C). Using a combination of both RIP
enrichment data and repression of gene expression data to
identify miRNA targets produced a high frequency of seed
matches in the most highly ranked targets for all three
miRNAs, and we therefore used this method to define our
target sets (Figure 3D). There was enrichment for prolifera-
tion related genes in the targets identified for miR-503 and
miR-494, but there were not enough target genes identified
for miR-103 to produce meaningful results (Additional
file 2) [38-40].Enrichment of sequences pairing to the 3′ end of the
miRNAs in the experimentally profiled miRNA targetome
To determine the sub-sequences of miR-503, −103,
and −494 that are used for target pairing, we exam-
ined enrichment of 6-mer sequences that pair diffe-
rent areas of the mature miRNAs in the 3′UTRs of
the experimentally identified targets (Figure 4A). As
expected, there was a high frequency of 6-mer se-
quences that pair to the seed region, positions 2–7, of
the mature miRNAs (Figure 4A). Surprisingly, there was
also a high frequency of sequences that pair the 3′ end of
the mature miRNAs (Figure 4A). In separately conducted
experiments, we observed the same phenomenon in tar-
gets identified by RIP-Chip and microarray gene expres-
sion profiling (Additional file 3). Nelson et al. previously
reported this same finding when they experimentally pro-
filed the targets of miR-103, and concluded that miR-103
utilized miRNA 3′ pairing for targeting, although they
did not further explore this observation experimentally
[41]. Based on the enrichment for sequences pairing
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Figure 3 Genome wide profiling of miR-503, −103, and −494 targets. (A) mRNAs enriched in the RIP-seq following miR-503, −103, or −494
transfection are also repressed. The Y-axis denotes the cumulative fraction of all mRNA transcripts profiled for each group of mRNAs denoted by
line color, and the X-axis indicates the level of repression for each mRNA transcript profiled with positive values indicating increased repression.
Orange: all mRNAs; Blue: mRNAs that contain the respective 7-mer miRNA seed match in their 3′UTR; Green: mRNAs that were 1.75 fold enriched
in the RIP; Purple: mRNAs that were 1.75 fold enriched in the RIP and that contain the respective 7-mer miRNA seed match in their 3′UTR.
Significance estimates were calculated with Student’s t-test. (B) mRNAs enriched in the RIPs had the highest frequency of the respective miRNA
seed matches. The X-axis denotes consecutive groups of 250 genes, ranked from most enriched to least enriched in the RIP-seq. (C) For miR-103,
and −494, mRNAs repressed in the gene expression experiments had the highest frequency of the respective miRNA seed matches. The X-axis
indicates consecutive groups of 250 genes, ranked from most repressed to least repressed. (D) The highest ranked miRNA targets had the highest
frequency of the respective miRNA seed matches. RIP enrichment and gene expression repression data were combined to rank miRNA targets.
The X-axis denotes consecutive groups of 250 genes, from most highly ranked to least highly ranked. For B, C, and D, The line is the frequency
indicated on the Y-axis of the respective 7-mer miRNA seed in the gene group compared to the frequency of the seed in all genes profiled.
For B, C, and D, n = 3. E combines gene expression data, n = 3, with RIP-seq data, n = 3.
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Figure 4 miRNA targeting utilizing pairing outside of the canonical miRNA 5′ seed region. (A) Enrichment of sequences pairing to the
3′ end of the miRNAs in the experimentally determined miRNA targetomes. The Y-axis indicates the frequency of a 6-mer in the experimentally
determined miRNA target mRNAs relative to all mRNAs profiled. 6-mers are organized step-wise in 1 nucleotide increments along the X-axis from
5′ end to 3′ end of the mature miRNA. (B) Different types of miRNA-target pairing. (C) Frequency of different types of miRNA pairing in RIP-Seq
enriched mRNAs. Bars are the frequency of mRNAs with the indicated type of miRNA-target pairing in the RIP enriched mRNAs, relative to the
frequency of mRNAs with the indicated type of miRNA-target pairing in all mRNAs profiled. (D) RIP-seq enriched mRNAs containing a supplementary
target site in their 3′UTR were significantly more repressed than all RIP-seq enriched mRNAs, but not more repressed than RIP-seq enriched mRNAs
that contain a perfect 5′ seed in their 3′UTR (p = 0.04 and 0.06, respectively, Student’s t-test). Each box and whiskers plot indicates gene expression
repression for genes that contain the type of miRNA-target pairing specified on the X-axis. Boxes extend from the 1st to 3rd quartile of gene expression
repression, the band is the median, and whiskers denote the minimum and maximum excluding outliers. (E) There were no significant differences in
miR-503 RIP enrichment in RIP enriched mRNAs with different types of miRNA-target pairing. Each box and whiskers plot indicates RIP enrichment for
mRNAs that contain the type of miRNA-target pairing site specified on the X-axis. For C, D, and E, 5′ mismatch seed + 3′ mismatch (blue) corresponds
to Compensatory in B; 5′ perfect seed match + 3′ mismatch (green) corresponds to Supplementary in B; and 5′ perfect seed match (purple and orange)
correspond to Canonical seed in B. *P < 0.05.
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and miR-103, we hypothesized that miR-503 and −103
were using supplementary or compensatory pairing to tar-
get mRNAs (Figure 4B). Supplementary pairing employsa perfect miRNA 5′ seed match with additional 3′ pairing,
and compensatory pairing uses additional 3′ pairing to
compensate for mismatches or bulges in the 5′ seed
match (Figure 4B)[16]. Although miR-494 targets also
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side of the miRNA 5′ seed region, the areas of enrich-
ment were more diffuse, making them more difficult to
investigate experimentally (Figure 4A).
To investigate the type of target pairing used by miR-
503 and −103, we began by further analyzing our RIP
and gene expression data. We first examined the fre-
quency of compensatory and supplementary pairing sites
in highly ranked targets. Since the most enriched 5′ 6-
mer for miR-503 was from position 1–6 (Figure 4A), for
miR-503 we used both a canonical 5′ position 2–7 seed
match, as well as a 5′ position 1–6 seed match. The fre-
quency of compensatory pairing sites in the target gene
set for either miR-503 or miR-103 was not higher than the
frequency of 5′ seed matches (Figure 4C & Additional
file 3). However, supplementary pairing sites were much
more frequent than the 5′ seed matches and compen-
satory pairing sites for both miR-503 and miR-103
(Figure 4C & Additional file 3).
Next we examined miRNA dependent RISC associ-
ation and repression of mRNA targets with compensa-
tory or supplementary pairing sites. mRNAs showing
high miR-503 dependent RISC association and contain-
ing supplementary pairing sites were significantly more
repressed than mRNAs showing only miR-503 depen-
dent RISC association (Figure 4D). There were no sig-
nificant differences in repression for miR-103 or in RISC
association for either miR-503 or miR-103 that was
dependent on pairing type (Figure 4E & Additional file
3). Taken together, this data strongly suggests miR-503
may utilize supplementary target pairing for repression.
There were no differences between compensatory target
pairing sites and the intact 5′ seed alone for both miR-
503 and miR-103, making it difficult to draw conclusions
as to utilization of compensatory target pairing.
Pairing of the 3′ and 5′ end of miR-503 is necessary for
direct targeting by miR-503 of the cell growth promoting
gene DDHD2
To further investigate the utilization of supplementary
target pairing by miR-503 in targeting genes that affec-
ted cell proliferation, we searched for candidate genes to
test experimentally based on three criteria: (1) sequences
in the 3′ UTR that paired the 5′ and 3′ end of miR-503
(Figure 5), (2) involvement in promoting cell prolifera-
tion, and (3) combined RIP-seq and RNA-seq gene
expression repression rank. We identified one candidate
gene, DDHD2, that contained a perfect miR-503 5′ seed
match with additional 3′ pairing, had been previously
shown to promote proliferation of breast cancer cells [42],
and was the highest ranked gene in the combined genome-
wide experiments that satisfied the first two criteria.
To experimentally determine the target pairing mecha-
nisms used by miR-503, we cloned the 3′UTR of DDHD2into luciferase reporter constructs, and constructed add-
itional reporter constructs of the 3′UTR of DDHD2 with
deletions of either the sequence pairing the 5′ end of
miR-503, the sequence pairing the 3′ end of miR-503,
or both (Figure 5A). miR-503 repressed expression of
the reporter with the intact 3′UTR of DDHD2, and
deleting the sequences pairing to the 5′ and 3′ portion
of miR-503 relieved repression, indicating that miR-503
functionally targets DDHD2 for repression through these
sites. Unexpectedly, deleting only the sequence pairing the
3′ end of miR-503 also significantly relieved repression by
miR-503 even though the 5′ seed remained intact, indicat-
ing that miR-503 requires pairing of its 3′ end in order to
target DDHD2 in addition to the 5′ perfect seed pairing
(Figure 5A). Deleting the sequence pairing to the 5′ seed
of miR-503 also significantly relieved repression, although
there was no significant difference in reporter activity
between the 3′ and 5′ deletion constructs (Figure 5A). To
further confirm functional targeting of DDHD2 by miR-
503, we transiently overexpressed miR-503 in proliferating
fibroblasts and HeLa cells. Transient overexpression of
miR-503 did not repress the transcript levels of DDHD2
in proliferating primary human fibroblasts (data not
shown) but did decrease protein levels in both fibroblasts
and HeLa cells, indicating miR-503 more strongly re-
presses DDHD2 expression through inhibition of transla-
tion than mRNA destabilization (Figure 5B).
The involvement of miR-503 in ER+ breast cancer
DDHD2 has previously been shown to be tumor promot-
ing in breast cancer by cooperating functionally with Myc
to stimulate breast cancer cell growth [42]. In addition,
DDHD2 was observed to be located in a region (8p11.23)
of high level copy number aberrations in breast tumors
[42]. Amplification of this area most frequently occurs in
estrogen receptor positive (ER+) breast tumors [42].
We used the MIRUMIR tool to query the prognostic
value of miR-503 expression levels in a published data set
of patients with high-risk ER+ breast cancers [43]. Patients
with high miR-503 expression had a significantly higher
survival probability than patients with low miR-503 expres-
sion (Figure 6A). Analysis of DDHD2 alterations using the
cBio portal revealed that DDHD2 tends to be amplified in
a variety of cancers, and most predominantly in breast in-
vasive carcinoma (~12% of cases) (Figure 6B). In addition,
patients with copy number alterations of DDHD2 had a
significantly lower survival probability than patients with-
out copy number alterations of DDHD2 (Figure 6C). This
data suggests miR-503 plays a role in breast cancer tumori-
genesis at least in part by targeting DDHD2.
Discussion
In this study, we experimentally determined the targe-
tomes of multiple miRNAs that repress cell proliferation,
Figure 5 Pairing of the 3′ and 5′ end of miR-503 is necessary for direct targeting by miR-503 of the proto-oncogene DDHD2. (A) Pairing
by the 3′ and 5′ end of miR-503 to the 3′UTR of DDHD2 is necessary to repress expression of the luciferase reporter construct. The Y-axis denotes
relative luciferase units from miR-503 transfected HEK293 cells normalized to control RNA transfected cells. The X-axis indicates the type of 3′UTR
(either wild-type or deletion as indicated) Error bars denote ± SD, n = 3. In the diagram, vertical lines indicate base pairing, dashes show deleted
base pairs, and numbers in parenthesis denote location in the 3′ UTR, not genomic coordinates. P-values were calculated by Student’s one tailed
t-test comparing miRNA normalized to Control siRNA luciferase activity with intact 3′ UTRs, to normalized activity with the respective miRNA
target site deleted 3′ UTRs. *P < 0.05. (B) miR-503 transfection decreased protein expression of DDHD2. DDHD2 protein levels following miR-503
transfection in fibroblasts and HeLa cells compared to Control siRNA transfection. Band intensities were quantified, normalized to GAPDH, and
shown relative to the Control siRNA.
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proto-oncogene DDHD2 by a unique non-canonical tar-
geting mode. While supplementary base-pairing outside
the 5′ seed has been noted before, to our knowledge,
this is the first time that a requirement for supplemen-
tary pairing has been shown for target repression even
when perfect complementarity in the canonical 5′ seed
exists. We began by screening for miRNA involvement
in primary cell proliferation, and identified miR-503, −103,
and −494 as regulators of primary cell proliferation.
We then constructed genome wide target sets for miR-
503, −103, and −494 using RIP and global gene expression
profiling methodologies. Our analysis of the target sets
revealed potentially widespread use of non-canonicaltargeting by the miRNAs to post transcriptionally regulate
gene expression. We went on to show that miR-503 tar-
gets the oncogene DDHD2 non-canonically, requiring 3′
pairing of miR-503 in addition to the normal 5′ pairing.
Our analysis further linked miR-503 to ER+ breast cancer
through DDHD2.
Recent advances in methodologies to profile the entire
miRNA targetome have uncovered extensive mediation
of RISC-mRNA association by non-canonical targeting
[18-21]. However, the effects of non-canonical targeting
on gene expression ranged from moderate at best, to sta-
tistically insignificant depending on the study [18,20,21].
This discrepancy may be due to differences in the reli-
ance on miRNA seed interactions to identify targets. In
Figure 6 miR-503 involvement in breast cancer. (A) Low miR-503 expression correlates with a lower survival probability in ER+ breast cancer
patients (p = 8.56e-06). Kaplan-Meier survival curves for patients with ER+ breast cancer expressing different levels of miR-503 were calculated
using the MIRUMIR tool. Number of patients: n = 37. (B) DDHD2 is frequently amplified in breast cancer. The bars are the frequency of DDHD2
copy number alterations in the different types of cancer indicated on the X-axis. The frequency of patients with DDHD2 amplification was
calculated using the cBio portal. Yellow: Deletion; Orange: Amplification. n = 1044. (C) Patients with copy number alterations in DDHD2 (purple
line) have a lower survival probably than those without amplifications in DDHD2 (green line) (p = 0.027). Kaplan-Meier survival curves were was
calculated using the cBio portal. n = 888.
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canonical targeting by miR-503 mediating both RISC-
target association and gene expression. We went on to
experimentally confirm that 3′ target pairing was neces-
sary for miR-503 to repress DDHD2. miR-503 targeting
of DDHD2 may represent an isolated case, but analysis
of our experimentally identified genome wide target set
suggests miR-503 uses 3′ target pairing to mediate gene
expression throughout its targetome.
In addition, we showed that miR-503 acts like a tumor
suppressor by non-canonically targeting the putative
oncogene DDHD2. DDHD2 was previously shown to
promote tumorigenesis in breast cancer by cooperating
functionally with Myc to enhance breast cancer cell
growth [42]. DDHD2 is located in a region of the gen-
ome that is frequently amplified in breast tumors, and
most frequently in ER+ breast tumors [42]. Although
the exact area amplified differs between tumors, several
other genes are located in the region and frequently
amplified in addition to DDHD2. However, of this groupof genes, only FGFR1 and DDHD2 were shown to func-
tion as oncogenes in breast cancer, and DDHD2 was
shown to have transforming potential that was not de-
pendent on FGFR1 expression [42]. Our analysis showed
that decreased miR-503 expression correlated with low pa-
tient survivability, and that DDHD2 copy number amplifi-
cations were most frequent in invasive breast carcinoma
and correlate significantly with low patient survivability.
Taken together, these data suggest that miR-503 may
function as a previously unknown tumor suppressor in
ER+ breast cancer, and that a critical component of its
tumor suppressor role could be the repression of DDHD2
via a non-canonical mechanism.
miR-503 has been shown to act as a tumor suppressor
in several cancers, and decreases in miR-503 expression
have been reported in multiple cancer types [26,30,32,44].
In addition, miR-503 has been shown to target multiple
oncogenes and regulators of proliferation [30,33,44,45].
miR-503 inhibits hepatocellular carcinoma, glioblasto-
ma multiforme, and non small cell lung cancer (NSCLC)
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cycle arrest, and reducing metastasis [26,30,32,46]. Add-
itionally, miR-503 also represses hepatocellular carcinoma
tumor angiogenesis by targeting the potent angiogenic fac-
tors FGF2 and VEGFA [32]. miR-503 has also been shown
to play a role in repressing endometrial cancer [44]. Con-
sidered as a whole, these studies suggest that miR-503
operates as a potent tumor suppressor that regulates mul-
tiple pathways that are frequently deregulated in tumori-
genesis. Moderate repression of multiple key regulatory
genes can have large phenotypic effects in concert, and
miR-503 may conceivably inhibit breast cancer tumori-
genesis by repressing multiple previously known targets in
addition to DDHD2.
Conclusions
In summary, we demonstrated that miR-503 represses
cell proliferation, and may function as a tumor suppres-
sor in ER+ cancer by utilizing non-canonical 3′ pairing
to target and repress the proto-oncogene DDHD2. In ad-
dition, we provided experimentally determined genome
wide target profiles of the proliferation related miRNAs
miR-503, −103, and −494. Our genomic approach to iden-
tifying the targetome of miRNAs in combination with
potential widespread use of non-canonical targeting me-
chanisms points to a broader role for several miRNAs in
mediating cellular processes.
Materials and Methods
Normal cell culture conditions
HeLa cells and human foreskin fibroblasts (ATCC CRL
#2091) were maintained in DMEM (Dulbecco’s Modified
Eagle’s Medium) supplemented with 10% FBS (Fetal
Bovine Serum) at 37°C under 5% CO2.
RNA oligos and transfections
miRNA guide and anti-guide mature sequences were
obtained from miRBase (http://www.mirbase.org/). Se-
quences for the siRNA against GFP (Control siRNA)
were obtained from [47]; guide: 5′Phos-CUGGAGUU-
GUCCCAAUUCCUU and anti-guide: 5′Phos-AGAAUU
GGGACAACUCCAGUU. Sequences for a scrambled
control siRNA (Control siRNA 2) were adapted from
[48]; 5′Phos-AAUUCUCCGAACGUGUCACGUUA and
5′Phos-ACGUGACACGUUCGGAGAAUUCA. RNA oligos
were ordered from IDT and corresponding oligos were
annealed in RNA annealing buffer (20 mM HEPES, pH 7.3,
50 mM KCl, 2 mM MgCl2) to form mature miRNA or
siRNA duplexes. Both the miRNA and Control siRNA oli-
gos contained 5′ phosphate and 3′ OH ends. The RNA
duplexes were transfected at a final concentration of 100
nM using Lipofectamine 2000 according to the manufac-
turer’s instructions. The miRNA inhibitors and control
were miRCURY Locked Nucleic Acid (LNA) miRNAInhibitors and Negative Control Inhibitor obtained from
Exiqon and transfected at a final concentration of 10 nM
using Lipofectamine 2000.
Cell counting assays
For miRNA overexpression experiments, fibroblasts
were seeded at 10,000 cells per well in 6-well plates.
Cells were cultured in DMEM supplemented with 10%
FBS. Cells were allowed to grow 24 hours, and then cells
were transiently transfected with miRNA or Control
siRNA duplexes (100 nM final concentration). 0, 24, 48,
and 72 hours after transfection, cells were trypsinized,
and counted in a hemocytometer. 9 fields were averaged
for each biological replicate. For miRNA inhibition
experiments, fibroblasts were seeded at 10,000 cells per
well in 6-well plates. Cells were cultured in DMEM
supplemented with 10% FBS. Cells were allowed to grow
24 hours, and then media was replaced with low serum
DMEM 0.1% FBS. 24 hours after replacement with
DMEM 0.1% FBS, cells were transiently transfected with
miRCURY Locked Nucleic Acid (LNA) miRNA Inhibi-
tors or Negative Control Inhibitor obtained from Exiqon
(10 nM final concentration). 0, 24, and 48 hours after
transfection, cells were trypsinized, and counted in a
hemocytometer. 9 fields were averaged for each bio-
logical replicate.
Flow cytometry
Fibroblasts were seeded at 50,000 cells per well in 6-well
plates. Cells were cultured in DMEM supplemented with
10% FBS. Cells were allowed to grow 24 hours, and then
cells were transiently transfected with miRNA, Control
siRNA, or Control siRNA 2 duplexes (100 nM final con-
centration). 24 hours after transfection, cells were trypsi-
nized, washed with PBS, and fixed for 24 hours in 70%
ethanol at −20°C. For Ki67 staining, after ethanol fixation,
cells were washed with Stain Buffer (BD Pharmingen), in-
cubated 30 minutes with FITC Mouse Anti-Human Ki67
antibody (BD Pharmingen), washed, and resuspended in
500 μl Stain Buffer with Propidium Iodide Staining Solu-
tion (5 μg/ml) (BD Pharmingen). For PI staining, after
ethanol fixation, cells were washed twice with PBS, and
resuspended in PI staining solution (50ug/mL PI with
100ug/mL RNase in PBS). Flow cytometry analysis for
Ki67 in primary human fibroblasts was done using a
FACsCalibur flow cytometer and 10,000 events above
threshold levels were counted for each sample (BD Biosci-
ences). Data analysis was done using FlowJo.
RISC immunoprecipitation
We used a protocol previously detailed in [34] with
some modifications. HeLa cells were grown in 10 cm2
tissue culture plates and transfected with either miRNA
mature duplexes or Control siRNA duplexes at a final
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24 hours, cells were washed twice with PBS, and 0.5 ml
of lysis buffer was added onto the cell monolayer
followed by incubation at 4°C for 30 minutes. Cell lysate
was collected by scraping and cleared by centrifugation
at 14,000 rpm at 4°C. Cleared lysate was then incubated
with 50 μl of protein-G beads (Roche) for 1 hour at
4°C (pre-clearing). Before pre-clearing, 50 μl of the
cleared lysate was removed as input for total RNA
profiling. Pre-cleared lysate was incubated with 15 μg
of Ago2 antibody (ab57113, Abcam) at 4°C for 3 hours.
After antibody incubation, 50 μl of protein-G beads
were added to the lysate and incubated for 1 hour at
4°C. Beads were washed 8 times with lysis buffer and
Ago2-RNA complexes were extracted by adding 1 ml
TRIzol reagent (Invitrogen) directly to the beads. RNA
extraction was carried out as per the manufacturers
instructions.Microarray
Total RNA or RNA isolated from the RISC immuno-
precipitations were amplified and biotin-labeled with
the Illumina TotalPrep RNA Amplification Kit (Life
Technologies). RNA expression was profiled on HumanHT-
12 v4 Expression BeadChips (Illumina) at the KECK
Biotechnology Resource Laboratory at Yale. Array data
can be found in the GEO repository under accession
number GSE4616.RNA-seq library preparation and sequencing
rRNA was removed using the Ribo-Zero rRNA Removal
Kit (Epicentre), and the remaining RNA was purified
using the RNeasy MinElute Cleanup Kit (Qiagen). RNA
was then fragmented using the NEBNext Magnesium
RNA Fragmentation Module (New England BioLabs),
and size selected using AMPure XP beads (Agencourt)
at 1.8× volume. The ends of the fragmented RNA were
then prepared for adaptor ligation using T4 Polynucleo-
tide Kinase (New England BioLabs), and the reaction
was cleaned up with the RNeasy MinElute Cleanup Kit
(Qiagen). Libraries were then prepared from the now
rRNA depleted, fragmented, size selected, and kinased
RNAs using the NEBNext Small RNA Library Prep Set
according to the manufacturers protocol (New England
BioLabs). Libraries were cleaned and further size se-
lected using 0.8× volume AMPure XP beads, and then
additional size selections with 1.0× beads were per-
formed as necessary. A minimum of 20 million paired
end 100 bp reads were generated for each replicate using
a HiSeq 2000 (Illumina) by the Genomic Sequencing
and Analysis Facility at the University of Texas at Austin.
RNA-seq data can be found in the GEO repository under
accession number GSE4616.RNA-seq data processing
Barcodes were removed, adaptors were removed using
Cutadapt, and reads mapping to rRNAs and tRNAs were
filtered. Reads were mapped to the human genome
(hg19) by TopHat2 software version 2.0.9 [49]. We com-
bined biological replicates and assigned an expression
value (FPKM) for each RefSeq gene with Cuffdiff [49].
To avoid denominator inflation in subsequent ratio cal-
culations, all FPKMs less than 1 were hard capped to 1.
RNA-seq gene expression repression
Repression of gene expression for each gene was calcu-
lated as the ratio of the FPKM in the miRNA transfec-
tion to the FPKM in the control transfection:
Repression ¼ FPKM for the control
FPKM for the miRNA
RNA-seq RISC immunoprecipitation enrichment
RNA-seq RISC immunoprecipitations (RIP) enrichment
was calculated as follows: RIP FPKMs were first normal-
ized to gene expression FPKMs, and then enrichment
was calculated as the ratio of the normalized miRNA
transfection to the normalized control transfection:
Enrichment ¼
FPKM for the miRNA RIP =
FPKM for the miRNA gene expression
FPKM for the control RIP =
FPKM for the control gene expression
Defining a miRNA target list using RIP enrichment and
gene expression repression
Target scores to rank each mRNA were generated by
averaging RIP enrichment values and gene expression
repression values. mRNAs with a score of 1.75 or greater
were designated as the target set.
Gene ontology analysis
Gene ontology analysis was performed with the GeneCodis
online tool [38-40].
Searching for non-canonical target pairing
The subsequences of miR-503 and miR-103 examined
for pairing were selected based off the subsequence
enrichment plots shown in Figure 4A. For miR-503, the
criteria used to search for compensatory sites (5′ mis-
match + additional 3′ pairing) were: (1) a 6-mer pairing
position 1–6 with 1 mismatch, (2) an 8-mer pairing pos-
ition 11–18 with 0 – 3 mismatches, and (3) a 1 base pair
wobble allowed in the length of the sequence separating
the 6-mer and 8-mer. To search for supplementary sites
(5′ perfect pairing + additional 3′ pairing) the criteria
used were: (1) a 6-mer perfectly pairing position 1–6, (2)
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and (3) a 1 base pair wobble allowed in the length of the
sequence separating the 6-mer and 8-mer. A slightly off-
set seed sequence (position 1–6) was used for miR-503
because it was slightly more enriched in the experimen-
tally identified targets (Figure 4A). For miR-103, the
criteria used to search for compensatory sites (5′ mis-
match + additional 3′ pairing) were: (1) a 6-mer pairing
position 2–7 with 1 mismatch, (2) an 8-mer matching
position 11–18 with 0 – 3 mismatches, and (3) a 1 base
pair wobble allowed in the length of the sequence sep-
arating the 6-mer and 8-mer. To search for supplemen-
tary sites (5′ perfect pairing + additional 3′ pairing) the
criteria used were: (1) a 6-mer perfectly pairing position
2–7, (2) an 8-mer pairing position 13–20 with 0 – 3
mismatches, and (3) a 1 base pair wobble allowed in the
length of the sequence separating the 6-mer and 8-mer.
Luciferase reporter assays
We cloned 0.9 kb of the 3′UTR of DDHD2 centered
around the putative miR-503 binding site into the
psi-CHECK2 plasmid (Promega) downstream from the
Renilla luciferase gene using XhoI and NotI restriction
sites. Forward primer (lower case indicates XhoI site):
TTGTTGctcgagTTTTCCTCTCCTCAGCTGCG.
Reverse primer (lower case indicates NotI site): CTCT
ATgcggccgcGCCTGTGGAATCTGAGAGCA. This plas-
mid was used to produce three mutant variants. In the
whole-site deletion variant, the entire 22 bp sequencing
corresponding to the length of miR-503 at its binding
site was deleted (QuikChange Lightning Mutagenesis
Kit, Agilent). In the 3′ deletion variant, the 6 bp se-
quence corresponding to positions 7–12 of the putative
binding site (Figure 5B) (and positions 11–16 of the
miRNA in a putative duplex) was deleted. In the 5′
deletion variant, the 6 bp sequence corresponding to
positions 17–22 of the putative binding site (Figure 5B)
(and positions 2–7 of the miRNA in a putative duplex)
was deleted.
HEK293 cells were plated in 24-well plates at 105
cells/well in DMEM supplemented with 10% FBS and
1% Pen-Strep and grown overnight (Hyclone, Gibco).
Each plasmid was co-transfected at 50 ng/well with
either miRNA or Control siRNA duplex at a concentra-
tion of 100 nM in triplicate (Lipofectamine, Invitrogen).
Cells were harvested 24 hours post-transfection and
luciferase activity was measured using the Promega Dual
Luciferase kit according to the manufacturer’s instruc-
tions. Data was first normalized per-well by dividing
Renilla luminescence by Firefly luminescence. Relative
luciferase activity was then calculated as the ratio of the
mean of the three biological replicates for each miRNA
transfected group to the mean of the corresponding
Control siRNA transfected group.Western blotting
Primary human fibroblasts or HeLa cells were seeded in
6-well plates at 5 × 104 cells/well in DMEM supple-
mented with 10% FBS (Hyclone, Invitrogen). 24 hours
after plating, miR-503 or Control siRNA duplexes were
transfected at a 100 nM concentration (Lipofectamine,
Invitrogen). Transfected cells were lysed at 24 hr, 48 hr,
72 hr, or 96 hr post-transfection.
Cell lysates were separated on 4-20% gradient SDS-
PAGE gels (Biorad) and proteins were transferred onto
PVDF membranes. Membranes were blocked with 5%
milk or 5% BSA in TBST and probed overnight with
primary antibody in blocking solution (DDHD2: 1/500,
Abcam, ab103965; GAPDH: 1/1000, Abcam, ab9486). The
membranes were washed, incubated with HRP-conjugated
secondary antibody in blocking solution (1/5000, Santa
Cruz Biotechnology, sc-2004), and washed again. HRP
substrate solution was added to the membranes, and incu-
bated for four minutes (Pierce). Blots were exposed to
autoradiographic film and developed (Carestream Kodak
Biomax). Images of the films were scanned and band
intensities quantified using a white-light transilluminator
imaging system (FlourChem Q, ProteinSimple).
Cancer survival and copy number alteration analysis
Survival probabilities of ER+ breast cancer patients were
generated with MIRUMIR (http://www.bioprofiling.de/
GEO/MIRUMIR/mirumir.html) [43]. Data on DDHD2
copy number alteration frequency and patient survival in
patients with different cancer types was generated using
cBio portal (http://www.cbioportal.org/public-portal/) [50].
For each cancer type the percentage of patients with
DDHD2 amplifications, and patient survival probabilities,
were calculated as an average of all data sets available for
this cancer type. P-values were calculated with a hypergeo-
metric distribution.
Statistical analysis
Statistical significance was estimated using a one-sided,
two sided, or paired Student’s t-test as indicated, assum-
ing unequal variance.
Additional files
Additional file 1: Spearman rank correlation between RNA-seq
FPKM and microarray intensity value for each gene profiled by both
RNA-seq and FPKM. The average FPKM and average microarray intensity
values of the biological replicates were calculated for all conditions.
Values in the table are the Spearman rank correlation coefficients
comparing the averaged RNA-seq FPKM and microarray intensity values.
Additional file 2: GO term enrichment for experimentally
determined miRNA targetomes for miR-503 and miR-494.
Additional file 3: Using RIP-ChIP and microarray gene expression
profiling to explore miRNA target pairing outside of the canonical
miRNA 5′ seed match. (A) Enrichment of sequences pairing to the
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RIP-ChIP and microarray expression profiling data. Bars are the frequency
indicated on the Y-axis of a 6-mer in the miRNA targetome relative to all
mRNAs profiled. 6-mers are organized along the X-axis from 5′ end to
3′ end of the mature miRNA. (B) Frequency of different types of miR-503-
target pairing in RIP-ChIP enriched mRNAs. Bars are the frequency of
mRNAs with the indicated type of miRNA-target pairing in the RIP
enriched mRNAs, relative to the frequency of mRNAs with the indicated
type of miRNA pairing in all mRNAs profiled. (C) Left: RIP-ChIP enriched
mRNAs containing a complementary target site in their 3′UTR are
significantly more repressed than all RIP-ChIP enriched mRNAs, but not
more repressed than all RIP-ChIP enriched mRNAs that only contain a
perfect 5′ seed match (p = 0.04 and 0.10, respectively, Student’s t-test).
Right: There were no significant differences in miR-503 RIP enrichment or
gene expression in RIP enriched mRNAs with different types of miRNA
pairing. (D) There were no significant differences between different types
of miR-103 target pairing in miR-103 RIP-seq enriched mRNAs in either
RIP enrichment (left) or gene expression repression (right). For C and D,
each box and whiskers indicates gene expression repression for genes
that contain the type of miRNA-target pairing specified on the X-axis.
Boxes extend from the 1st to 3rd quartile of gene expression repression,
the band is the median, and whiskers denote the minimum and
maximum excluding outliers. Each plot indicates RIP enrichment or gene
expression repression for mRNAs that contain the type of miRNA-target
pairing specified on the X-axis.
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